Dapagliflozinin Diyabetik Sıçanlarda Sub-akut Maruziyet Sonrası Renal Etkilerinin Değerlendirilmesi-Reference-Cited by-同舟云学术

Dapagliflozinin Diyabetik Sıçanlarda Sub-akut Maruziyet Sonrası Renal Etkilerinin Değerlendirilmesi

Published:2023-08-19 Issue: Volume: Page:
ISSN:2458-8806
Container-title:Hacettepe University Journal of the Faculty of Pharmacy
language:en
Short-container-title:HUJPHARM

Author:

BORAN Tugce¹^ORCID,ULUS KARACA Bahar²,KARAGÖZ KÖROĞLU Ayça³^ORCID,ERCAN Feriha³,ÖZHAN Gül⁴^ORCID

Affiliation:

1. İSTANBUL ÜNİVERSİTESİ, ECZACILIK FAKÜLTESİ, ECZACILIK PR.

2. İSTANBUL ÜNİVERSİTESİ, ECZACILIK FAKÜLTESİ, ECZACILIK BİLİMLERİ (DR)

3. MARMARA ÜNİVERSİTESİ, TIP FAKÜLTESİ

4. İSTANBUL ÜNİVERSİTESİ, ECZACILIK FAKÜLTESİ

Abstract

Dapagliflozin (DAPA), a sodium glucose co-transporter 2 (SGLT2) inhibitor, is a therapy option for the treatment of type 2 diabetes. Although several studies have demonstrated its protective effects on the kidney, the FDA warns about the risk of DAPA-induced nephrotoxicity. SGLT2 inhibitors may induce oxidative stress and inflammation in the kidney due to their mechanism of action. In the present study, it was aimed to clarify the molecular effects of DAPA on the kidney. Streptozotocin (STZ)-induced diabetes was initiated by single injection of STZ (35 mg/kg b.w.) after a two-week high-fat diet in male rats. Diabetic rats were administered with DAPA at 10 mg/kg b.w., by oral gavage for 28 days. The oxidative stress, inflammation and apoptosis induction potentials of DAPA were evaluated in kidney homogenates. The morphological changes and apoptosis were investigated by histological examinations. It was observed that DAPA treatment reduced oxidative parameters. The inflammatory mediators increased in diabetic control group, however, this increase was slightly inhibited by DAPA treatment. According to the histological examinations, DAPA ameliorated the diabetes-induced changes and apoptosis. As a result, DAPA showed a protective effect on the kidney by alleviating oxidative stress and inhibiting inflammation and apoptosis. However, further studies are needed to determine the long-term effects of DAPA on the kidney in diabetics by focusing on different mechanisms and individual differences.

Funder

Research Fund of Istanbul University

Publisher

Hacettepe University

Subject

General Pharmacology, Toxicology and Pharmaceutics

Reference40 articles.

1. 1. FDA, 2014. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/202293s003lbl.pdf. (accessed 5 January 2020).

2. 2. FDA, 2019. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209091s002lbl.pdf. (accessed 5 January 2020).

3. 3. FDA 2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/202293s024lbl.pdf (accessed 10 June 2020).

4. 4. Joe E. 2019. Dapagliflozin approved to reduce risk for heart failure hospitalization in type 2 diabetes. NEJM J Watch 2019. https://www.jwatch.org/fw115953/2019/10/22/dapagliflozin-approved-reduce-risk-heart-failure. (accessed 30 January 2020).

5. 5. FDA, 2016. FDA strengthens kidney warnings for diabetes medicines canagliflozin (Invokana, Invokamet) and dapagliflozin (Farxiga, Xigduo XR) | https://www.fda.gov/drugs/fda-drug-safety-podcasts/fda-strengthens-kidney-warnings-diabetes-medicines-canagliflozin-invokana-invokamet-and (accessed January 5, 2020).